Litcius/Paper detail

Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial

Ephraim L. Tsalik, Nadine Rouphael, Ruxana T. Sadikot, Maria C. Rodriguez‐Barradas, Micah T. McClain, Dana M Wilkins, Christopher W. Woods, Geeta K. Swamy, Emmanuel B. Walter, Hana M. El Sahly, Wendy A. Keitel, Mark J. Mulligan, Bonifride Tuyishimire, Elisavet Serti, Toshimitsu Hamasaki, Scott Evans, Varduhi Ghazaryan, Marina S. Lee, Ebbing Lautenbach, Ghina Alaaeddine, Jennifer J. Zreloff, Nina McNair, Colleen S. Kraft, David L. Roberts, Sharon Bergquist, Nour Beydoun, Jesse J. Waggoner, Merin Kalangara, Matthew H. Collins, Alexandra W. Dretler, Amer Ryan Bechnak, Laura Oh, Zhihong Yuan, Brian J. Burrows, Emily R. Ko, Weixiao Dai, Lijuan Zeng

2022The Lancet Infectious Diseases25 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAzithromycinPlaceboProcalcitoninRespiratory tract infectionsInternal medicineLower respiratory tract infectionPopulationAdverse effectClinical trialAntibioticsRespiratory systemSepsisPathologyBiologyAlternative medicineEnvironmental healthMicrobiologyAntibiotic Use and ResistancePneumonia and Respiratory InfectionsSepsis Diagnosis and Treatment
Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial | Litcius